Skip to main content
Theralase Technologies Inc. logo

Theralase Technologies Inc. — Investor Relations & Filings

Ticker · TLT ISIN · CA88337V1004 LEI · 529900NI3Y8GLE2IBF28 TSXV Manufacturing
Open in API
Filings indexed 698 across all filing types
Latest filing 2020-09-30 Capital/Financing Update
Country CA Canada
Listing TSXV TLT

About Theralase Technologies Inc.

https://theralase.com/

Theralase Technologies Inc. designs, develops, manufactures, and markets patented laser technology platforms for both bio-stimulative and bio-destructive medical applications. The company operates two core divisions. The first is Cool Laser Therapy (CLT), which utilizes proprietary super-pulsed laser systems for therapeutic purposes, focusing on pain management, inflammation reduction, tissue repair, and the effective elimination of chronic knee pain. The second is Anti-Cancer Therapy (ACT), which employs patented light-activated Photo Dynamic Compounds (PDCs) combined with laser technology for destructive applications, specifically targeting the safe and effective destruction of cancer, bacteria, and viruses.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the company's proposal to extend the expiry date of share purchase warrants. It discusses the terms of the warrant extension and mentions that the extension is subject to final acceptance by the TSX Venture Exchange. There are no financial statements, detailed financial performance data, or comprehensive report content. The document is short (3439 characters) and serves as an announcement of a capital structure change related to warrants. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2020-09-30 English
Other securityholders documents - English.pdf
Governance Information Classification · 100% confidence The document is titled 'BY-LAW NO. 4' and contains detailed provisions relating to the governance and conduct of affairs of Theralase Technologies Inc. It includes sections on interpretation, business of the corporation, directors, meetings, officers, shares, dividends, and other governance-related topics. There is no indication of financial data, audit results, earnings, or shareholder meeting results. The content is focused on internal rules and governance structure rather than financial performance or announcements. Therefore, this document fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full by-law text, not a brief announcement or summary.
2020-09-28 English
News release - English.pdf
AGM Information Classification · 95% confidence The document is a press release dated September 24, 2020, from Theralase Technologies Inc. It provides detailed instructions on voting procedures for the company's virtual Annual General and Special Meeting (AGM) scheduled for that day. The text focuses on how shareholders and proxyholders can participate and vote during the meeting, including access links and phone numbers. There is no financial data, report content, or results disclosed. The document is not the AGM materials themselves but an announcement about the voting process for the AGM. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or AGM Information (AGM-R). However, since it is about voting procedures and not the results or materials of the AGM, it aligns more closely with AGM Information (AGM-R), which covers presentations and materials shared during the AGM or related procedural information. The document length is 5689 characters, which is consistent with a detailed announcement rather than a brief notice. Hence, the classification is AGM Information (AGM-R).
2020-09-24 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release from Theralase Technologies providing an update on their Phase II clinical study for bladder cancer. It discusses patient enrollment, treatment progress, efficacy results, and regulatory interactions with the FDA, including a Fast Track Approval application. The content is focused on clinical trial progress and company updates rather than detailed financial data or comprehensive report disclosures. The document is approximately 8,370 characters, which is relatively short and typical for a press release. It does not contain financial statements, management discussion and analysis, or detailed regulatory filings. It is not an earnings release, annual report, or interim report. It is also not a regulatory filing or certification. The document is best classified as a Capital/Financing Update (CAP) because it provides updates on clinical trial progress and regulatory status, which are material to the company's development and capital market activities, but it is not a formal financial report or regulatory filing. Therefore, the most appropriate classification is CAP with high confidence.
2020-09-24 English
Other.pdf
Regulatory Filings Classification · 100% confidence The document is an Officer's Certificate pursuant to a regulatory instrument (National Instrument 54-101) related to communication with beneficial owners of securities. It certifies compliance with proxy material distribution requirements for an upcoming annual general meeting. The document is short (1098 characters) and primarily a certification letter without substantive financial data or detailed report content. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the report or meeting materials themselves.
2020-09-03 English
Certificate re dissemination to shareholders.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a short communication from TSX Trust Company confirming the mailing of proxy-related materials for Theralase Technologies Inc. It lists items such as Proxy with Request for Financial Statements, Voting Instruction Form, Notice of Meeting Combined with Information Circular, and Proxy Return Envelope. The document does not contain any financial data or detailed report content but rather confirms the distribution of proxy materials. The length is only 1291 characters, indicating it is an announcement rather than a full report. This fits the category of Proxy Solicitation & Information Statement (PSI), as it relates to materials sent to shareholders for voting purposes.
2020-09-03 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.